SecBot SecBot
424B5 ·Filed Aug 10, 2026

SLN

Silence Therapeutics plc
BEARISH
Impact 7/10
Horizonimmediate Processed3mo ago SEC0001193125-26-342633
Notable filing: 424B5
Actionable Insight ▼ Bearish

The $150M offering is a significant dilutive event that will pressure the stock near-term, but the positive Phase 2 data provides a fundamental catalyst that may support the stock. Monitor the final offering price and number of ADSs sold; the 60-day lock-up expiration could create additional selling pressure. The company expects cash runway into 2029, reducing near-term financing risk.

DirectionBearish
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$14.72
T+0 close · Aug 10, 2026 · via day close
Latest settled
+34.51%
T+60 · $19.80
Vs SPY
+35.00%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 11 $14.72entry
  2. T+1 · 3mo ago −7.74%α −8.00% · $13.58
  3. T+5 · 3mo ago −4.21%α −3.81% · $14.10
  4. T+20 · 2mo ago −7.95%α −6.89% · $13.55
  5. T+60 · 13d ago +34.51%α +35.00% · $19.80
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Silence Therapeutics is conducting a $150M underwritten public offering of ADSs, announced concurrently with positive Phase 2 SANRECO topline results for divesiran in polycythemia vera. The offering represents significant dilution (~27% of current market cap) but capitalizes on the stock's recent catalyst-driven appreciation to fund Phase 3 development. The net tangible book value was $27.7M ($0.59/ADS) as of June 30, 2026, and the offering will cause substantial dilution to new investors, though exact per-ADS dilution is not calculable as the offering price is not yet set.

Key Facts

  • $150M public offering of ADSs (preliminary, subject to completion)
  • Offering priced on August 10, 2026, the same day positive Phase 2 SANRECO topline results were announced
  • Net tangible book value was $27.7M ($0.59/ADS) as of June 30, 2026
  • Underwriters have a 30-day option to purchase additional ADSs
  • Proceeds to fund continued clinical development and general corporate purposes
  • Company expects cash runway into 2029 with net proceeds
  • Lock-up agreements for officers and directors for 60 days after prospectus date

Financial Impact

$150M offering represents ~27% of $559M market cap; net tangible book value was $27.7M as of June 30, 2026; exact dilution per ADS not calculable as offering price is placeholder

dilutioncash_positionshare_count

Risk Factors

  • Immediate and substantial dilution to existing shareholders
  • Potential for further equity offerings given the $300M shelf and ATM facility
  • Execution risk for Phase 3 trial initiation and regulatory approval
  • Stock price may decline as new shares enter the market

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001193125-26-342633
Document: 0001193125-26-342633-index-headers.html0001193125-26-342633
Document: 0001193125-26-342633-index.html0001193125-26-342633
Document: 0001193125-26-342633.txt0001193125-26-342633

Track record

15 reports on SLN

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +28.19% at T+60 after the Aug 10, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $19.72 Now $19.80 +0.42% settles Nov 24
  2. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $19.80 Now $19.80 −0.00% settles Nov 19
  3. Nov 12, 20264d ago DEFA14A Neutral 4/10 Entry $19.80 Now $19.80 −0.00% settles Nov 19
  4. Nov 12, 20264d ago 8-K Neutral 5/10 Entry $19.80 Now $19.80 −0.00% settles Nov 19
  5. Nov 5, 202611d ago SC 13G Neutral 4/10 Entry $19.72 to $19.80 Now $19.80 +0.41% ▲ +0.41% −2.88% vs SPY
  6. Oct 19, 202628d ago DEFA14A Bullish 7/10 Entry $19.61 to $19.78 Now $19.80 +0.97% ▲ +0.87% +0.79% vs SPY
  7. Oct 19, 202628d ago DEFA14A Bullish 8/10 Entry $19.58 to $19.78 Now $19.80 +1.12% ▲ +1.02% +1.17% vs SPY
  8. Oct 19, 202628d ago 8-K Bullish 9/10 Entry $19.58 to $19.78 Now $19.80 +1.12% ▲ +1.02% +1.17% vs SPY
  9. Oct 13, 20264w ago SC 13G/A Neutral 3/10 Entry $8.98 to $19.67 Now $19.80 +120.49% ▲ +119.04% +118.59% vs SPY
  10. Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $8.98 to $19.67 Now $19.80 +120.49% ▲ +119.04% +118.59% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 10, 2026